Moreover, the fact that Ang-2 expression is co-expressed with VEGF in HCC and connected to worse survival of HCC patients treated with sorafenib indicated that Ang-2 may contribute to the resistance of anti-VEGF therapy [21, 28]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.